ACTA1 and metabolic dysfunction-associated steatohepatitis: Similar to in the NASH model, IGF-I treatment clearly improved fibrosis (Fig. 3e) and decreased expression of activated HSCs markers, αsma and Vimentin, respectively (Fig. 3f), indicating that IGF-I ameliorated fibrosis in the cirrhotic model.